73
Participants
Start Date
September 30, 2011
Primary Completion Date
September 30, 2012
Study Completion Date
November 30, 2012
Rifaximin
Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
Cornell CRS (7804), New York
NY Univ. HIV/AIDS CRS (401), New York
HIV Prevention & Treatment CRS (30329), New York
AIDS Care CRS (1108), Rochester
Univ. of Rochester ACTG CRS (1101), Rochester
Pittsburgh CRS (1001), Pittsburgh
Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia
Georgetown University CRS (GU CRS) (1008), Washington D.C.
IHV Baltimore Treatment CRS (4651), Baltimore
Unc Aids Crs (3201), Chapel Hill
Duke Univ. Med. Ctr. Adult CRS (1601), Durham
The Ponce de Leon Center CRS (5802), Atlanta
Univ. of Miami AIDS CRS (901), Miami
Alabama Therapeutics CRS (5801), Birmingham
The Ohio State Univ. AIDS CRS (2301), Columbus
Case CRS (2501), Cleveland
Metro Health CRS (2503), Cleveland
Univ. of Cincinnati CRS (2401), Cincinnati
Northwestern University CRS (2701), Chicago
Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago
Washington U CRS (2101), St Louis
University of Colorado Hospital CRS (6101), Aurora
UCLA CARE Center CRS (601), Los Angeles
Ucsf Aids Crs (801), San Francisco
Stanford CRS (501), Palo Alto
University of Washington AIDS CRS (1401), Seattle
Massachusetts General Hospital ACTG CRS (101), Boston
Brigham and Women's Hosp. ACTG CRS (107), Boston
Beth Israel Deaconess Med. Ctr., ACTG CRS (103), Boston
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477), Newark
The Miriam Hosp. ACTG CRS (2951), Providence
Puerto Rico-AIDS CRS (5401), San Juan
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK